logo
Select company
Select metric
Ticker Information

Ticker

EBS

Company Name

EMERGENT BIOSOLUTIONS INC

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NYSE

EMERGENT BIOSOLUTIONS INC - Capital Expenditures to Operating Cash Flow Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

EBS - CapEx/OCF Historical data
DateCapital ExpenditureCapital Expenditures to Operating Cash FlowNet Cash Flow - Operations
6/30/2025$ -32.1M0%$ 169M
3/31/2025$ -30.3M0%$ 110.1M
12/31/2024$ 15M25.55%$ 58.7M
9/30/2024$ 25M14.65%$ 170.7M
6/30/2024$ 39.4M51.17%$ 77M
3/31/2024$ 47.3M0%$ -84.9M
12/31/2023$ 51.6M0%$ -206.3M
9/30/2023$ 63.8M0%$ -145.6M
6/30/2023$ 79.1M0%$ -279.6M
3/31/2023$ 98.7M0%$ -180.8M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • EMERGENT BIOSOLUTIONS INC's latest trailing twelve months (TTM) CapEx/OCF stands at 34.16%.
  • Over the past 5 years, EMERGENT BIOSOLUTIONS INC's average CapEx/OCF has been 50.71%.
  • The median CapEx/OCF for EMERGENT BIOSOLUTIONS INC during this period was 53.97%
  • EMERGENT BIOSOLUTIONS INC reached its highest CapEx/OCF over the past 5 years at 90.35%.
  • The lowest CapEx/OCF recorded by EMERGENT BIOSOLUTIONS INC in the same timeframe 14.65%

EMERGENT BIOSOLUTIONS INC's CapEx/OCF vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

CapEx/OCF Benchmarks
CompanyCapEx/OCF
OFIX : ORTHOFIX MEDICAL INC 98.39%ESPR : ESPERION THERAPEUTICS INC -ORGO : ORGANOGENESIS HOLDINGS INC -MYGN : MYRIAD GENETICS INC -AVNS : AVANOS MEDICAL INC 22.49%SIGA : SIGA TECHNOLOGIES INC 0.05%VREX : VAREX IMAGING CORP 39.03%EHAB : ENHABIT INC 6.63%INNV : INNOVAGE HOLDING CORP 19.06%EOLS : EVOLUS INC -

Definition of Capital Expenditures to Operating Cash Flow

[Calculation] The CapEx to Operating Cash Flow ratio, measures how much of a company’s operating cash flow is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by net operating cash flow [NCFO].
CapEx / CF - Operations
(=) CapEx/OCF
CapEx/OCF for EMERGENT BIOSOLUTIONS INC is calculated as follows: CapEx [ $ 141.1M ] / CF - Operations [ $ 413M ]
(=) CapEx/OCF [ 34.16% ]

EBS - Capital Expenditures to Operating Cash Flow, Last 5 years

14.65%

Minimum

Sep 30, 2024

90.35%

Maximum

Sep 30, 2021

50.71%

Average

53.97%

Median

CapEx/OCF Benchmark Analysis

The chart above depicts the distribution of CapEx/OCF for companies in the Total Stock Market. The average CapEx/OCF of the companies is 31.8% with a standard deviation of 29.52%.
The following table provides additional summary stats:
CapEx/OCF in the Market:
filtered constituents2.35K
min0.01%
max128%
average31.8%
median22.41%
std29.52%